Sanofi: restructures deal with Regeneron Pharmaceuticals
(CercleFinance.com) - Sanofi and Regeneron Pharmaceuticals have announced that they have restructured their global Immuno-oncology Discovery and Development Agreement for new immune-oncology cancer treatments, an agreement that dates back to 2015 and which was due to end in mid-2020.
This revision provides for ongoing collaborative development of two clinical stage bispecific antibody programs. This provides Sanofi increased flexibility to advance its early-stage immuno-oncology pipeline independently.
Sanofi will pay Regeneron 462 million dollars, representing the balance of payments due in immune-oncology, up to 120 million dollars in development costs for the two selected clinical-stage bispecific antibodies, plus the termination fee for the other programs under the original immuno-oncology agreement.
Copyright (c) 2019 CercleFinance.com. All rights reserved.